Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,000,000 Ordinary shares of 25 pence each.
- Transaction Date: August 22, 2011.
- Price Range: Highest price paid was 1,299 pence per share; lowest price paid was 1,238.5 pence per share.
Material Changes
Following the cancellation of the repurchased shares, the Company's Treasury holdings increased to 502,996,816 shares. This represents 9.00% of the total issued share capital and 9.89% of the total voting rights. The number of shares in issue (excluding Treasury shares) stands at 5,086,569,720.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,086,569,720) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (502,996,816) and its impact on voting rights (9.89%).
- Note that this filing is a transactional update and does not contain operational or financial performance data for the period.